[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Gangnam Severance Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":565},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,41,76,104,131,150,180,210,231,249,271,291,317,339,362,383,402,423,446,467,486,506,526,546],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100641076","opiranserin-for-minimally-invasive-cholecystectomy-100641076",false,"NCT07620665","Opiranserin for Minimally Invasive Cholecystectomy","Comparison of Opiranserin\u002FAcetaminophen Versus Ibuprofen\u002FAcetaminophen for Postoperative Pain Management After Minimally Invasive Cholecystectomy: A Randomized, Controlled, Non-inferiority Trial","Inclusion Criteria:\n\n* Adult patient undergoing minimally invasive cholecystectomy\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to acetaminophen, NSAIDs, opiranserin, or fentanyl.\n* pre-existing chronic pain,\n* clinically significant ECG findings (QRS \\> 200 msec, QTcF \\>450 msec)\n* severe renal impairment\n* severe hepatic impairment","ALL","19 Years",{"count":19,"type":20},88,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to evaluate whether the combination therapy of opiranserin and acetaminophen is non-inferior to the combination of non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen for postoperative pain management after minimally invasive cholecystectomy.\n\nThis is a single-center, randomized, controlled, non-inferiority clinical trial in adult patients undergoing minimally invasive cholecystectomy. Participants will be randomly assigned to either the Treatement group (opiranserin + acetaminophen) or the control group (NSAIDs + acetaminophen) in a 1:1 ratio to compare the analgesic efficacy and safety between the two analgesic regimens.",[26,27],"Cholecystectomy, Laparoscopic","Cholecystectomy, Robotic","RECRUITING","2026-06-16",{"date":31,"type":32},"2026-06-18","ACTUAL",{"date":34,"type":32},"2026-06-10",{"date":36,"type":20},"2028-05-30",{"name":38,"class":39},"Gangnam Severance Hospital","OTHER",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":56,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":40},"100631818","ai-based-rehabilitation-for-hip-and-knee-surgery-patients-100631818","NCT07505628","AI-based Rehabilitation for Hip and Knee Surgery Patients","Evaluation of the Efficacy and Safety of AI-based Rehabilitation Exercise After Hip and Knee Arthroplasty","Inclusion Criteria:\n\n* Adult patients aged 19 years or older.\n* Patients scheduled to undergo hip or knee arthroplasty at Gangnam Severance Hospital or affiliated hospitals of Chung-Ang University Medical Center (Chung-Ang University Hospital, Gwangmyeong Hospital, Hyundai Hospital).\n* Patients with a preoperative Functional Ambulatory Category (FAC) stage of 4 or 5 (For hip fracture cases, pre-fracture FAC stage will be considered).\n* Patients capable of downloading and using mobile applications on smart devices (smartphones or tablets) independently without researcher assistance.\n* Patients who fully understand the study's purpose and procedures and have voluntarily signed the informed consent form.\n\nExclusion Criteria:\n\n* Individuals unable to perform exercises due to severe musculoskeletal pain.\n* Individuals with severe dizziness or poor vision that prevents them from following exercise videos provided by the digital treatment.\n* Individuals with visual impairment that causes difficulty in recognizing the monitor\u002Fdevice screen.\n* Individuals requiring long-term inpatient treatment due to unstable vital signs.\n* Individuals with partial or total lower-limb amputation due to trauma, disease, or congenital defects.\n* Individuals classified as vulnerable subjects (as defined by clinical research ethics guidelines).\n* Any other individuals deemed ineligible for participation at the discretion of the principal investigator.",{"count":49,"type":20},106,[23],"This study aims to evaluate the efficacy and safety of an AI-based home rehabilitation application (\"Exersite Rehab\") for patients who have undergone hip or knee arthroplasty(Total Knee Arthroplasty (TKA), Total Hip Arthroplasty (THA) or hip fracture surgery). Following surgery, effective rehabilitation is crucial for functional recovery; however, many patients face barriers to consistent in-hospital exercise. This interventional study divides participants into two groups to compare outcomes. The experimental group will perform a 12-week home-based rehabilitation program guided by an AI application that provides real-time posture correction and monitoring. In contrast, the control group will perform the same exercise protocol using traditional printed educational brochures.The primary objective is to determine if the AI-based digital healthcare solution significantly improves physical function, measured by the Functional Ambulatory Category(FAC), compared to conventional methods. Secondary outcomes including pain levels(Visual Analog Scale (VAS)) and joint-specific functional scores (Knee Society Score (KSS), Harris Hip Score (HHS)) will also be assessed over the 12-week period.",[53,54,55],"Total Knee Arthroplasty","Total Hip Arthroplasty (THA)","Hip Fracture Surgery",[57,58,59,60,61,62,63,64,65,66],"Arthroplasty","TKA","THA","Hip Fracture","Digital Therapeutics","AI Rehabilitation","Mobile Application","Home-based Exercise","Remote Monitoring","Physical Function","NOT_YET_RECRUITING","2026-03-26",{"date":70,"type":32},"2026-04-01",{"date":72,"type":20},"2026-03-09",{"date":74,"type":20},"2028-12-31",{"name":38,"class":39},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":103,"locationsCount":4},"100616862","endocrine-therapy-base-on-21-gene-rs-100616862","NCT07311122","Endocrine Therapy Base on 21-gene RS","Comparison of Endocrine Therapy Plus Ovarian Function Suppression and Chemotherapy Based on 21-gene RS in Young Age (≤ 50) Women (CUSTOM): Multi-center Registry Study","CUSTOM","Inclusion Criteria:\n\n1. Histologically confirmed breast cancer.\n2. Age ≤50 years at initial diagnosis.\n3. Premenopausal at diagnosis, defined as any of the following:\n\n   A. History of menstruation within 6 months prior to diagnosis. B. Serum FSH \\\u003C 30 mIU\u002FmL. C. If criteria A or B are unavailable, women aged ≤50 years are considered premenopausal.\n4. Underwent curative-intent breast cancer surgery between January 2012 and December 2021.\n5. Pathologic tumor stage pT1-pT3 after surgery.\n6. Pathologic nodal stage pN0-pN1 after surgery.\n7. Hormone receptor-positive disease by immunohistochemistry (IHC): estrogen receptor (ER) and\u002For progesterone receptor (PR) positive (≥1% positive cells or Allred score ≥3).\n8. HER2-negative disease per ASCO\u002FCAP guidelines: IHC 0 or 1+; if IHC 2+, in situ hybridization (FISH or SISH) negative.\n9. Oncotype DX® performed, meeting one of the following Recurrence Score (RS) ranges:\n\nA. pN0: RS 11-25. B. pN1: RS ≤25.\n\nExclusion Criteria:\n\n1. Evidence of distant (systemic) metastasis at diagnosis.\n2. Postmenopausal status at diagnosis, defined as any of the following:\n\n   A. Prior bilateral oophorectomy before the breast cancer diagnosis (considered postmenopausal).\n\n   B. Prior unilateral oophorectomy alone is not considered postmenopausal (classified as premenopausal).\n\n   C. Bilateral oophorectomy performed after breast cancer surgery for therapeutic purposes is not an exclusion; such patients will be categorized as having received ovarian function suppression (OFS).\n\n   D. Serum FSH ≥ 30 mIU\u002FmL.\n3. Hormone receptor-negative or HER2-positive disease.\n4. Insufficient or unclear data regarding the type of adjuvant therapy received.\n5. History of another malignancy treated before the breast cancer diagnosis, except for thyroid cancer and non-melanoma skin cancer.\n6. Bilateral breast cancer.\n7. Receipt of neoadjuvant systemic therapy prior to surgery.","20 Years",{"count":86,"type":20},4000,"OBSERVATIONAL","Among patients aged ≤50 years with hormone receptor-positive, HER2-negative breast cancer and pathologic nodal stage pN0-1-limited to those with an Oncotype DX® Recurrence Score (RS) of 11-25 for pN0 and ≤25 for pN1-, we will investigate the followings:\n\ni) Real-world patterns of adjuvant therapy (systemic chemotherapy and endocrine therapy) and radiotherapy according to N stage and Oncotype DX® RS.\n\nii) Clinicopathologic characteristics of each patient subgroup by adjuvant treatment modality and RS category.\n\niii) Survival outcomes and independent prognostic factors according to RS. iv) Survival analyses by adjuvant treatment modality, stratified by RS category, clinical risk, and N stage.\n\nThrough these analyses, we aim to establish clinical evidence on whether endocrine therapy combined with ovarian function suppression (OFS) can substitute for adjuvant chemotherapy in HR+\u002FHER2- patients with pN0-1 disease within the above RS ranges, and-if so-to define the patient subsets for whom this substitution is appropriate.",[90],"Breast Cancer",[92,93,94,95,96],"Breast cancer","Hormone receptor-positive","Oncotype DX","Chemotherapy","Ovarian function suppression","2025-12-16",{"date":99,"type":32},"2025-12-30",{"date":101,"type":20},"2026-01-01",{"date":74,"type":20},{"name":38,"class":39},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":112,"minAge":17,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":21,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},"100450537","a-study-to-reduce-persistent-post-mastectomy-pain-using-opioid-free-anesthesia-100450537","NCT05146778","A Study to Reduce Persistent Post-mastectomy Pain Using Opioid-free Anesthesia","A Single-blinded Randomized-controlled Study to Reduce Persistent Post-mastectomy Pain Using Multimodal Opioid-free Anesthesia","RELIEF","Inclusion Criteria:\n\n* All of patients will undergo mastectomy with or without immediate breast reconstruction.\n\nExclusion Criteria:\n\n* Previous history of breast surgery\n* Allergy to drug\n* Other cancer history\n* Underlying psychologic disorder\n* Patients with chronic pain requiring pain killers\n* Baseline SpO2 \\\u003C95%\n* Left ventricular EF \\\u003C40%\n* Bradycardia as HR \\\u003C50 bpm\n* BMI \\>35kg\u002Fm2\n* Pregnant woman","FEMALE","80 Years",{"count":115,"type":20},230,[23],"In 230 patients undergoing mastectomy, the investigators will compare opioid-free anesthesia (OFA) versus conventional opioid-based anesthesia in terms of chronic pain. The enrolled patients will be randomly assigned into two groups with 1:1 ratio. Chronic pain will be evaluated at 1 year after mastectomy based on the Breast Cancer Pain Questionnaire (BCPQ). Baseline pain sensitivity test and psychologic evaluation will be done before operation.",[90,119,120,121],"Mastectomy","Pain, Chronic","Pain, Post Operative","2025-11-18",{"date":124,"type":32},"2025-11-21",{"date":126,"type":32},"2021-12-16",{"date":128,"type":20},"2027-10-31",{"name":38,"class":39},1,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":4},"100600152","additional-prognostic-value-of-tumor-grade-beyond-the-21-gene-recurrence-score-100600152","NCT07093775","Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score","Prognostic Implication of Tumor Grade in Patients With Node-negative Breast Cancer Aged ≤ 50 Years With 21-gene Recurrence Scores of 11-25","Inclusion Criteria:\n\n* Patients with hormone receptor-positive, HER2-negative early-stage breast cancer\n* Patients treated between January 2011 and December 2023\n* Patients with available clinicopathologic data and 21-gene Oncotype DX assay results confirmed through electronic medical records\n\nExclusion Criteria:\n\n* Patients with breast cancer under the age of 20\n* Patients diagnosed with stage IV breast cancer\n* Patients for whom clinicopathologic data cannot be retrieved from electronic medical records",{"count":86,"type":20},"To evaluated the prognostic significance of tumor grade in patients with node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2-negative breast cancers treated according to RS-guided strategies.",[90,141],"Tumor Grade","2025-07-22",{"date":144,"type":32},"2025-07-30",{"date":146,"type":20},"2025-07",{"date":148,"type":20},"2026-03",{"name":38,"class":39},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":112,"minAge":84,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":160,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":4},"100593852","phase-2-immune-checkpoint-blockade-after-partial-breast-irradiation-by-pembrolizumab-in-early-tnbc-100593852","NCT07011823","Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC","Phase II Trial of Immunochemotherapy and Partial Breast Irradiation in Early TNBC With Immune-cold Tumor Environment (KEY-MELT)","KEY-MELT","Inclusion Criteria:\n\n* Breast cancer patients aged 20 years or older with clinical stage IIA or higher on imaging studies\n* Patients with triple-negative breast cancer confirmed on tissue biopsy\n* Cold immune tumor environment with tumor-infiltrating lymphocytes (TILs) \\\u003C30% and PD-L1 Combined Positive Score (CPS) \\\u003C10 on immunohistochemical staining of biopsy specimens\n* Patients with no prior history of breast cancer\n* Patients with no prior history of chemotherapy or radiation therapy\n* Patients scheduled to receive partial breast irradiation\n* Patients with ECOG performance status of 0-2\n* Patients who voluntarily signed the informed consent form for study participation\n\nExclusion Criteria:\n\n* Patients with non-triple-negative breast cancer on tissue biopsy\n* Patients scheduled for surgery without neoadjuvant chemotherapy\n* Patients with TILs ≥30% or PD-L1 CPS ≥10 on immunohistochemical staining of biopsy specimens (immune-hot tumor)\n* Patients with recurrent breast cancer or de novo stage IV disease\n* Patients who have previously received chemotherapy and\u002For radiation therapy to the ipsilateral breast and chest prior to study participation\n* Patients unable to receive neoadjuvant chemotherapy and Pembrolizumab\n* Vulnerable research subjects who are unable to participate voluntarily in the study due to physical\u002Fmental disabilities",{"count":159,"type":20},20,[161],"PHASE2","A single-arm, single-institution study to induce phenotypic changes in the tumor microenvironment by delivering 8Gy partial breast irradiation in immune-cold triple-negative breast cancer confirmed by PD-L1 and TILs. Additional tissue biopsy will be performed following radiation therapy. Subsequently, neoadjuvant chemotherapy including Pembrolizumab will be administered to evaluate whether pathological complete response rates are improved.",[164],"Triple-Negative Breast Neoplasm",[166,167,168,169,170,171],"Immune-cold microenvironment","Triple-negative breast cancer","Partial Breast Irradiation","Pembrolizumab","KeyNote-522","Immunochemotherapy","2025-06-02",{"date":174,"type":32},"2025-06-10",{"date":176,"type":20},"2025-07-16",{"date":178,"type":20},"2033-07-31",{"name":38,"class":39},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":112,"minAge":84,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":21,"phases":191,"briefSummary":193,"conditions":194,"keywords":199,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":40},"100464871","phase-4-ofs-in-premenopausal-node-breast-cancer-with-low-genomic-risk-100464871","NCT05333328","OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk","Endocrine Therapies With Ovarian Function Suppression in Premenopausal Node+ Early Breast Cancer With Low Genomic Risk (INTERSTELLAR Trial, KBCSG-25)","INTERSTELLAR","Inclusion Criteria:\n\n* ER+HER2- breast cancer\n* Premenopausal and age \\\u003C=50\n* T1 or T2\n* N1 including micrometastasis\n* Genomic Low Risk by OncoFREE test® (1-20)\n\nExclusion Criteria:\n\n* Postmenopausal women\n* ER-negative breast cancer","50 Years",{"count":190,"type":20},418,[192],"PHASE4","Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®).\n\nIn these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.",[90,195,196,197,198],"Estrogen Receptor Positive Tumor","HER2-negative Breast Cancer","Premenopausal Breast Cancer","Node-positive Breast Cancer",[90,195,196,197,198,200,201],"Multigene assay","Ovarian-function suppression","2025-05-18",{"date":204,"type":32},"2025-05-22",{"date":206,"type":32},"2023-02-06",{"date":208,"type":20},"2033-01",{"name":38,"class":39},{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":21,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":130},"100580624","comparison-of-ropivacaine-poloxamer-407-hydrogel-and-tap-block-for-postoperative-pain-management-in-laparoscopicrobotic-gastrectomy-100580624","NCT06839716","Comparison of Ropivacaine-Poloxamer 407 Hydrogel and TAP Block for Postoperative Pain Management in Laparoscopic\u002FRobotic Gastrectomy","Prospective Randomized Controlled Study of Ropivacaine-Poloxamer 407 Based Gel Application and TAP Block for Postoperative Pain Management Following Laparoscopic\u002FRobotic Gastrectomy","Inclusion Criteria:\n\n1. Patients with a histologically confirmed diagnosis of gastric adenocarcinoma prior to surgery.\n2. Patients who have undergone a complete surgical resection (R0 resection).\n3. Patients with an ASA (American Society of Anesthesiologists) score of 3 or below.\n4. Patients aged 20 years or older.\n5. Patients who have undergone laparoscopic or robotic gastrectomy\n\nExclusion Criteria:\n\n1. Patients under 19 years of age.\n2. Presence of ascites or peritoneal metastasis.\n3. Patients who have undergone preoperative chemotherapy or radiotherapy.\n4. Diagnosis of malignancies other than gastric cancer.\n5. Uncontrolled diabetes, autoimmune diseases, hypertrophic scars, or keloid history affecting wound healing.\n6. History of allergy or adverse reactions to Ropivacaine or other local anesthetics.\n7. Pregnant women.\n8. Patients with preoperative chronic pain conditions, including CRPS.\n9. Patients with long-term preoperative use of opioid analgesics.\n10. Patients with psychiatric disorders deemed likely to interfere with study participation.\n11. Patients with severe liver disease, renal disease, or arrhythmia.",{"count":218,"type":20},134,[23],"This study aims to determine whether Ropivacaine-Poloxamer 407 hydrogel provides non-inferior pain control compared to TAP block for patients undergoing minimally invasive gastrectomy. The results will guide postoperative pain management practices and enhance recovery protocols for gastric cancer surgery.",[222],"Gastric Cancer","2025-02-23",{"date":225,"type":32},"2025-02-25",{"date":227,"type":32},"2025-02-01",{"date":229,"type":20},"2026-03-31",{"name":38,"class":39},{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":21,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":247,"leadSponsor":248,"locationsCount":130},"100580759","comparison-of-full-robotic-instrumentation-and-assistant-controlled-laparoscopic-instrumentation-in-robotic-distal-gastrectomy-100580759","NCT06841484","Comparison of Full Robotic Instrumentation and Assistant-Controlled Laparoscopic Instrumentation in Robotic Distal Gastrectomy","Clinical Outcomes of Full Robotic Instrumentation Versus Assistant Controlled Laparoscopic Instrumentatin in Robotic Distal Gastrectomy: Randomized Pilot Study","Inclusion Criteria:\n\n1. Patients with histologically confirmed gastric adenocarcinoma prior to surgery.\n2. Patients who have undergone a complete (R0) resection.\n3. Patients with an ASA (American Society of Anesthesiologists) score of 3 or below.\n4. Patients undergoing robotic radical distal gastrectomy.\n\nExclusion Criteria:\n\n1. Patients under 19 years of age.\n2. Patients who have received preoperative chemotherapy or radiotherapy.\n3. Patients diagnosed with stage IV gastric cancer due to distant metastasis.\n4. Patients diagnosed with malignancies other than gastric cancer.\n5. Patients scheduled to undergo total gastrectomy.\n6. Patients requiring total omentectomy.",{"count":239,"type":20},36,[23],"This pilot study aims to provide valuable insights into the optimal surgical approach for robotic distal gastrectomy. By comparing full robotic procedures with assistant-controlled techniques, the results may guide future practice, enhancing surgical efficiency, reducing costs, and improving patient outcomes.",[222],"2025-02-21",{"date":245,"type":32},"2025-02-24",{"date":227,"type":32},{"date":229,"type":20},{"name":38,"class":39},{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":21,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":130},"100526013","partial-synovectomy-in-articular-side-of-quadriceps-tendon-verified-to-reduce-crepitus-in-retrospective-study-100526013","NCT06129214","Partial Synovectomy in Articular Side of Quadriceps Tendon Verified to Reduce Crepitus in Retrospective Study","Partial Synovectomy in Articular Side of Quadriceps Tendon Reduces Crepitus After Posterior Stabilized Total Knee Arthroplasty : a Randomized, Controlled Trial","Inclusion Criteria:\n\n1.Patients who scheduled to perform both total knee arthroplasty(TKA) using posteiror crucitate sustain type (PS)\n\nExclusion Criteria:\n\n1. Lost follow up (Including death of patient)\n2. Unexpected complication (e.g) Infection, periprosthetic fracture)\n3. Patella resurfacing\n4. Canceled surgical treatment\n5. Refused to enrolled study\n6. Too much radiological or physicological variance shown between either knee",{"count":257,"type":20},78,[23],"Crepitus causing unsatisfied result to patients after posterior stabilized total knee arthroplasty. Recent retrospective study demonstrated removal of hyperplastic synovium in distal quadriceps caused reduce of crepitus. However, this study has limitation of time gap exist between arms, different in observation time and bias caused by retrospective review. Thus aim of this study is that by randomized trial, verified hyperplastic synovium in distal quadriceps causing crepitus.\n\nTarget enrolled patients in this study are scheduled to perform both total knee arthroplasty. Experimental group is randomized side (right or left) of knee, and control group is other side of knee. Both arms decided by randomized number table. Crepitus measured after 3mo, 6mo, 1year after surgical treatment",[261,262,263],"Osteoarthritis, Knee","Rheumatoid Arthritis, Knee","Spontaneous Osteonecrosis of Knee","2025-02-19",{"date":243,"type":32},{"date":267,"type":32},"2023-10-16",{"date":269,"type":20},"2025-10-06",{"name":38,"class":39},{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":21,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":130},"100575951","ropivacaine-poloxamer-407-gel-for-pain-control-after-open-gastrectomy-100575951","NCT06778954","Ropivacaine-Poloxamer 407 Gel for Pain Control After Open Gastrectomy","Prospective Randomized Controlled Trial of Ropivacaine-Poloxamer 407 Based Gel Application on Postoperative Pain After Open Gastrectomy","Inclusion Criteria:\n\n1. Patients with a histologically confirmed diagnosis of gastric adenocarcinoma prior to surgery.\n2. Patients who have undergone a complete surgical resection (R0 resection).\n3. Patients with an ASA (American Society of Anesthesiologists) score of 3 or below.\n4. Patients aged 20 years or older.\n\nExclusion Criteria:\n\n1. Patients under 19 years of age.\n2. Presence of ascites or peritoneal metastasis.\n3. Patients who have undergone preoperative chemotherapy or radiotherapy.\n4. Diagnosis of malignancies other than gastric cancer.\n5. Uncontrolled diabetes, autoimmune diseases, hypertrophic scars, or keloid history affecting wound healing.\n6. History of allergy or adverse reactions to Ropivacaine or other local anesthetics.\n7. Pregnant women.\n8. Patients with preoperative chronic pain conditions, including CRPS.\n9. Patients with long-term preoperative use of opioid analgesics.\n10. Patients with psychiatric disorders deemed likely to interfere with study participation.\n11. Patients with severe liver disease, renal disease, or arrhythmia.",{"count":279,"type":20},48,[23],"The study evaluates the efficacy of Ropivacaine-Poloxamer 407 hydrogel in reducing postoperative pain following open gastrectomy.",[222],"2025-02-13",{"date":285,"type":32},"2025-02-14",{"date":287,"type":32},"2025-01-30",{"date":289,"type":20},"2025-12-31",{"name":38,"class":39},{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":16,"minAge":298,"maxAge":299,"enrollmentInfo":300,"targetDuration":4,"studyType":21,"phases":302,"briefSummary":303,"conditions":304,"keywords":305,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":130},"100569120","pilot-study-for-high-output-drainage-removal-after-gastrectomy-100569120","NCT06690112","Pilot Study for High Output Drainage Removal After Gastrectomy","A Pilot Study Comparing the Incidence of Intra-abdominal Complications According to the Removal of the Drainage Tube in Patients With Large Amounts of Drainage After Gastrectomy in Gastric Cancer Patients","Inclusion Criteria:\n\n* Patients pathologically diagnosed with gastric adenocarcinoma before surgery.\n* Patients eligible for complete surgical resection (R0 resection).\n* Patients with an ASA (American Society of Anesthesiologists) score of 3 or lower.\n* Patients with more than 300 ml of drainage in the 24 hours on the postoperative day 4.\n\nExclusion Criteria:\n\n* Patients aged 80 or older.\n* Patients with stage IV gastric cancer.\n* Patients with ascites due to peritoneal metastasis.\n* Patients with evident intra-abdominal complications following surgery.\n* Patients who require the insertion of additional percutaneous drainage due to insufficient drainage.\n* Patients who underwent incomplete gastric resection (R1 or R2 resection).\n* Patients diagnosed with cancers other than gastric cancer.\n* Patients with a history of major intra-abdominal surgery or abdominal radiotherapy that may hinder the normal absorption of intra-abdominal fluid.\n* Patients with more than 500 ml of drainage in the 24 hours on postoperative day 4.\n* Patients presenting with any of the following clinical signs or diagnoses:\n\n  1. Postoperative pancreatic fistula (POPF), defined as drain amylase levels (Drain amylase; D-amy) more than 3 times higher than serum amylase levels (Serum amylase; S-amy).\n  2. Fever exceeding 37.8℃.\n  3. Presence of any of the following clinical markers of inflammation:\n\n     i. White blood cell count (WBC) \\> 15,000\u002FμL ii. C-reactive protein \\> 200 mg\u002FL\n  4. Observation of non-serous drainage fluid, such as:\n\n     i. Chylous fluid: Milky-colored fluid. ii. Bloody or sanguineous fluid: Intra-abdominal fluid suggestive of ongoing hemorrhage.\n* Vulnerable subjects will not be enrolled in the study, including minors, pregnant women, neonates, adults with impaired consent capacity, individuals in institutional facilities, students, employees of medical institutions or research centers, pharmaceutical company employees, military personnel, unemployed persons, impoverished individuals, homeless individuals, terminally ill patients, or patients in emergency situations.","18 Years","79 Years",{"count":301,"type":20},60,[23],"\\*Objective: The study aims to evaluate whether there is a difference in intra-abdominal complication rates between patients discharged with or without a drainage tube following gastrectomy with high postoperative drainage (≥300ml\u002Fday).\n\n\\*Study Design: This is an open-label randomized controlled trial (RCT) involving two groups. Patients will be randomly assigned to either maintain the drainage tube (control) or have it removed (experimental) before discharge. The primary endpoint is the incidence of intra-abdominal complications within one month post-surgery.\n\n\\*Participants:\n\nThe study targets 60 patients (30 per group) who meet the following criteria:\n\nDiagnosed with gastric adenocarcinoma and underwent curative gastrectomy (R0 resection).\n\nPostoperative drainage of 300-500 ml\u002Fday on the 4th day after surgery. Patients with stage IV cancer, peritoneal metastasis, or postoperative complications requiring additional intervention are excluded.\n\n\\*Methods: All participants will follow standard postoperative care except for the removal or retention of the drainage tube. Follow-up will occur at 1 and 3 weeks post-discharge, with clinical examinations and imaging (if necessary) to monitor for complications such as infection or abscess. The study's total observation period will last four weeks from the surgery date.\n\n\\*Data Collection: Data will include patient demographics, surgical details, postoperative management, and the occurrence of complications. Drainage volumes will be recorded daily for those discharged with a tube, and tube removal will occur based on specific criteria.",[222],[306,307,308],"Drainage tube","Gastrectomy","High output","2025-01-06",{"date":311,"type":32},"2025-01-08",{"date":313,"type":32},"2024-01-01",{"date":315,"type":20},"2025-07-31",{"name":38,"class":39},{"id":318,"slug":319,"hasResults":11,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":324,"enrollmentInfo":325,"targetDuration":4,"studyType":21,"phases":327,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":130},"100562839","phase-3-comparison-partial-versus-total-omentectomy-in-minimal-invasive-distal-gastrectomy-for-ct34a-gastric-cancer-klass-10-100562839","NCT06608381","Comparison Partial Versus Total Omentectomy in Minimal Invasive Distal Gastrectomy for cT3\u002F4a Gastric Cancer (KLASS-10)","Comparison Between Partial Omentectomy and Total Omentectomy During Minimally Invasive Radical Distal Gastrectomy for Clinical T3 and T4a Gastric Cancer; Multicenter Randomized Clinical Trial (KLASS-10)","Inclusion Criteria:\n\n* Histologically proven adenocarcinoma of the stomach\n* Age between 20 to 85 years old\n* ECOG PS 0-1, ASA class I-III\n* Endoscopically Borrmann type I, II, III\n* Clinical T3 and T4a tumors with or without regional lymph node metastases (cT3N0M0\\~T4aN3M0)\n* Capable of minimal invasive radical subtotal gastrectomy with R0 resection in preoperative examinations\n* Patients who signed an written consent form approved by the Institutional Review Board(IRB) after receiving sufficient explanations of the contents of the clinical trial\n* Domestic patients who are able to follow up for 3 years after surgery\n\nExclusion Criteria:\n\n* Confirmed distant metastasis in preoperative examinations\n* Confirmed metastasis in abdominal cavity or distant organs during surgery\n* Confirmed no infiltration of the serosa layer or unable to confirm the tumor location during surgery (sT1-2)\n* Confirmed invasion of surrounding organs (sT4b)\n* History of previous gastrectomy or greater omentum related surgery\n* Patients who underwent preoperative treatment (chemotherapy, radiotherapy, or endoscopic submucosal dissection) for recently diagnosed gastric cancer\n* Synchronous or metachronous malignancies, which underwent surgery, chemotherapy or radiotherapy within 5 years\n* Patients judged to be inappropriate for the study by the physician. (ex. Pregnancy)\n* Patients refused to participate after random assignment\n* Surgery is not performed until 30 days after consenting to participate\n* Patients who has participated in another on-going clinical trial, which is related surgical procedures and survival.","85 Years",{"count":326,"type":20},440,[328],"PHASE3","For advanced gastric cancer, surgical resection is the only curable therapeutic strategy. According to minimally invasive approach is adopted in various field of oncologic surgery, laparoscopic gastrectomy with lymph node dissection is becoming a standard not only for early gastric cancer but also for advanced gastric cancer.\n\nThe greater omentum is an organ is known to play a role in removing bacteria in the abdominal cavity as a primary defense. Complete resection of the greater omentum has been considered essential to ensure the elimination of micrometastasis during surgery for advanced gastric cancer. However, the oncological effect of total omentectomy is still lack of evidence. Especially in minimal invasive gastrectomy, total omentectomy procedure is known to increases the operating time, increase the risk of bleeding, colonic injury, and postoperative complications such as intra-abdominal abscess, ascites, anastomotic leakage, ileus and wound infections. Therefore, in the case of minimal invasive surgery in early gastric cancer, omentectomy is omitted usually or routinely. Partial omentectomy preserves the omentum more than 3cm away from the gastro-epiploic vessels. Advanced energy devices facilitate partial omentectomy during laparoscopic gastrectomy.\n\nAccording to the Japanese Gastric Cancer Treatment Guidelines, partial omentectomy (omentum preservation) is feasible for T1 or T2 tumors, and total omentectomy is recommended for clinical T3 or deeper tumors. However, the National Comprehensive Cancer Network(NCCN) guideline suggests total omentectomy and the European Society for Medical Oncology(ESMO) guideline does not mentioned about it.\n\nIt is still controversial whether total omentectomy should be performed in advanced gastric cancer. Therefore, we aimed to verify the non-inferiority of partial omentectomy, oncologic safety compared with total omentectomy via multicenter randomized clinical trial.",[222],"2024-09-19",{"date":333,"type":32},"2024-09-23",{"date":335,"type":32},"2024-06-26",{"date":337,"type":20},"2031-12-30",{"name":38,"class":39},{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":21,"phases":348,"briefSummary":349,"conditions":350,"keywords":352,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":130},"100448640","effects-of-analgesia-nociception-index-ani-guided-analgesia-on-postoperative-bowel-function-100448640","NCT05122078","Effects of Analgesia Nociception Index (ANI)-Guided Analgesia on Postoperative Bowel Function.","Effects of Analgesia Nociception Index (ANI)-Guided Analgesia on Postoperative Bowel Function Recovery in Laparoscopic Colorectal Surgery: A Prospective Randomized-controlled Study","Inclusion Criteria:\n\n* Patients over 19 years who undergo laparoscopic colorectal surgery for colorectal cancer at Gangnam Severance Hospital, Seoul, South Korea.\n\nExclusion Criteria:\n\n* Emergency surgery\n* Patients with history of open abdominal surgery\n* Patients with arrhythmia\n* Patients with pacemaker insertion\n* Patients with history of heart transplantation\n* Patients taking medications that may affect ANI (antimuscarinics, alpha-agonists, beta blockers)\n* Patients with chronic opioid medication.\n* Cognitive impairment\n* Unable to read consent form (eg illiterate, foreigner, etc.)",{"count":347,"type":20},80,[23],"Investigators will examaine the effects of Analgesia Nociception Index (ANI)-guided analgesia on postoperative bowel function recovery in laparoscopic colorectal surgery. This is a prospective randomized-controlled study.\n\nInvestigators will randomly divide the patients into two groups. In ANI group, remifentanil infusion rate during anesthesia will be adjusted according to ANI monitoring. In Control group, remifentanil infusion rate during anesthesia will be adjusted according to the conventional method of blood pressure and heart rate monitroing. And Investigators will evalualte the bowel function recovery in both groups after surgery, and compare between the two groups.",[351],"Postoperative Bowel Function Recovery",[353],"Analgesia Nociception Index (ANI)","2024-09-02",{"date":356,"type":32},"2024-09-05",{"date":358,"type":32},"2021-11-29",{"date":360,"type":20},"2025-10-14",{"name":38,"class":39},{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":11,"sex":112,"minAge":17,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":21,"phases":371,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":40},"100511225","eeg-and-ani-guided-anesthesia-and-quality-of-recovery-100511225","NCT05936671","EEG and ANI Guided Anesthesia and Quality of Recovery","Quality of Recovery After Electroencephalogram and Nociception Level-guided Versus Standard Anesthesia Care in Female Patients Undergoing Laparoscopic Gynecological Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\nAdult female patients who are scheduled to undergo laparoscopic gynecological surgery.\n\n1. Total laparoscopic hysterectomy with\u002Fwithout salpingo-oophorectomy\n2. Laparoscopic myomectomy\n3. Laparoscope-guided salpingo-oophorectomy\n4. Laparoscope-guided ovarian cystectomy\n5. Laparoscope-guided enucleation of ovarian cyst\n\nExclusion Criteria:\n\n1. Patients with nonregular sinus cardiac rhythm\n2. Patients with implanted pacemakers\n3. Patients on antimuscarinic agents, α2-adrenergic agonists, β1-adrenergic antagonists, antiarrhythmic agents\n4. pregnant or breastfeeding women\n5. Patients who are unable to communicate",{"count":370,"type":20},126,[23],"This study aims to assess whether electroencephalogram (EEG) and nociception level-guided anesthesia can improve quality of recovery after laparoscopic gynecological surgery compared with standard care. Patients will be randomly assigned to either EEG and Analgesia Nociception Index (ANI)-guided anesthesia group (EEG-and-ANI-Guided group) or usual care group (control group). Primary outcome is 15-item Quality of Recovery (QoR-15) score at postoperative day (POD) 1. Secondary outcomes included remifentanil consumption during anesthesia, occurrence of awareness with recall, incidence of undesirable intraoperative movement, emergence time, postoperative pain scores, quality of recovery score at POD 2, and length of hospital stay.",[374],"Laparoscopic Gynecological Surgery","2024-08-14",{"date":377,"type":32},"2024-08-15",{"date":379,"type":32},"2023-07-13",{"date":381,"type":20},"2025-06-25",{"name":38,"class":39},{"id":384,"slug":385,"hasResults":11,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":11,"sex":16,"minAge":390,"maxAge":391,"enrollmentInfo":392,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":396,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":130},"100500775","frontal-alpha-asymmetry-and-pediatric-emergence-delirium-100500775","NCT05800639","Frontal Alpha Asymmetry and Pediatric Emergence Delirium","Mediation Role of Perioperative Electroencephalogram Frontal Alpha Asymmetry to Pediatric Emergence Delirium","Inclusion Criteria:\n\n* Children aged 2-8 year\n* Children with an American Society of Anesthesiologists (ASA) physical status of I-II\n* Children who are scheduled to undergo elective ophthalmological requiring general anesthesia\n\nExclusion Criteria:\n\n* Emergency surgery\n* Patients with developmental delays\n* Patients with neurological or psychiatric diseases associated with symptoms of agitation, anxiety, attention deficit, sleep disturbances\n* Patients with autism\n* Patients with a recent history (within one month) of receiving general anesthesia\n* Patients with congenital or genetic diseases that may influence brain development","2 Years","8 Years",{"count":347,"type":20},"This study aimed to investigate whether the association between the preoperative anxiety level and emergence delirium involves EEG frontal alpha asymmetry in pediatric patients undergoing ophthalmic surgery under general anesthesia. The investigators hypothesized that EEG frontal alpha asymmetry contributes a significant portion of the preoperative anxiety - emergence delirium association in pediatric patients. Mediation analysis will be performed to estimate the relationships between preoperative anxiety of children (modified Yale Preoperative Anxiety Scale (mYPAS)), EEG frontal alpha asymmetry, and emergence delirium (Pediatric Assessment of Emergence Delirium (PAED) scale).",[395],"Emergence Delirium",{"date":377,"type":32},{"date":398,"type":32},"2023-04-06",{"date":400,"type":20},"2025-04-20",{"name":38,"class":39},{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":21,"phases":411,"briefSummary":412,"conditions":413,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":417,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":130},"100485177","quadratus-lumborum-block-after-cytoreductive-surgery-and-hyperthermic-intra-peritoneal-chemotherapy-100485177","NCT05597683","Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy","Quadratus Lumborum Block for Analgesia After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (CRS and HIPEC): a Double-blind Randomized Controlled Trial","Inclusion Criteria:\n\n\\- Adult patients who are scheduled to undergo cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (CRS and HIPEC)\n\nExclusion Criteria:\n\n1. Allergy to local anesthetics or fentanyl\n2. Chronic pain\n3. Drug abuse\n4. Patients who are unable to use patient-controlled analgesia\n5. Skin infection at site for quadratus lomborum block\n6. pregnant or breatfeeding women\n7. Patients who are unable to communicate",{"count":410,"type":20},50,[23],"This study aims to assess whether transmusculr quadratus lomborum block (QL block) can reduce postoperative pain after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (CRS and HIPEC). Patients will be randomly assigned to either QL block group or control group. Ultrasound-guided bilateral transmuscular quadratus lomborum block will be performed in QL block group using 0.375% ropivacaine. Multimodal analgesic regimen including acetaminophen, nonsteroidal antiinflammatory drugs (NSAIDs), and rescue opioids will be used in every patient. Primary outcome is opioid consumption for 24 hours after surgery. Secondary outcomes included pain scores, time to first rescue analgesics, quality of recovery score, length of hospital stay.",[414,415,416],"Cytoreductive Surgery","Hyperthermic Intra-peritoneal Chemotherapy","Peritoneal Cancer",{"date":377,"type":32},{"date":419,"type":32},"2022-11-15",{"date":421,"type":20},"2025-01-10",{"name":38,"class":39},{"id":424,"slug":425,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":21,"phases":432,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":130},"100554299","binaural-sound-for-remimazolam-maintenance-100554299","NCT06497283","Binaural Sound for Remimazolam Maintenance","The Effect of Intraoperative Binaural Sound on Remifentanil Dose Required for General Anesthesia Using Remimazolam: a Randomized, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Patients scheduled for general anesthesia\n2. Patients aged 20-60\n3. Patients with American Society of Anesthesiologist physical status classification 1-2\n4. Patients with ideal body weight 50-80 kg\n\nExclusion Criteria:\n\n1. Patients with hearing disability\n2. Patients using opioids or sedatives in 1 week\n3. Patients who are dependent for alcoholics or drugs\n4. Patients with hypersensitivities to remimazolam or remifentanil\n5. Patients with arrhythmia, cardiovascular disease, heart failure, or hypovolemia\n6. Patients with liver failure",{"count":431,"type":20},72,[23],"It is important to decrease the remifentanil dose for general anesthesia maintenance when using remimazolam. We will evaluate the effect of binaural sound on general anesthesia maintenance with remimazolam infusion.",[435,436,437],"General Anesthesia","Prostate Cancer Stage","Uterine Myoma","2024-08-07",{"date":440,"type":32},"2024-08-09",{"date":442,"type":32},"2024-07-12",{"date":444,"type":20},"2025-02-28",{"name":38,"class":39},{"id":447,"slug":448,"hasResults":11,"nctId":449,"briefTitle":450,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":112,"minAge":452,"maxAge":4,"enrollmentInfo":453,"targetDuration":4,"studyType":21,"phases":455,"briefSummary":456,"conditions":457,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":130},"100526538","effect-of-sarcopenia-on-clinical-outcome-of-total-knee-arthroplasty-100526538","NCT06136039","Effect of Sarcopenia on Clinical Outcome of Total Knee Arthroplasty","Inclusion Criteria:\n\n* A woman aged 60 or older who is undergoing TKA due to degenerative osteoarthritis of the knee joint at the our institution.\n\nExclusion Criteria:\n\n1. Male\n2. Under 60 years of age\n3. Patients with a history of rheumatoid arthritis, traumatic joint disease, and post-infection joint disease\n4. Patients who cannot undergo tests for muscle weakness diagnosis A. Patients unable to walk B. Patients unable to stand alone due to conditions like cerebral palsy or brain disorders C. Patients unable to use muscle strength\n5. Patients considered inappropriate for recruitment in this study based on the judgment of the research team.","60 Years",{"count":454,"type":20},150,[23],"As human life expectancy increases, the prevalence of degenerative osteoarthritis of the knee joints is steadily rising, leading to a significant surge in the frequency of total knee arthroplasty (TKA). However, research on sarcopenia in the population that comprises the primary recipients of these orthopedic joint surgeries has been notably lacking. Since the release of the 2019 Consensus update on sarcopenia by the Asian Walking Group for Sarcopenia (AWGS) in 2020, research on sarcopenia has gained momentum in various domains. Yet, as previously mentioned, the field of orthopedics still lags behind in investigating sarcopenia. Therefore, it is believed that establishing the relationship between sarcopenia and surgical outcomes in the elderly, who are the primary targets of orthopedic joint replacement surgery, could offer insights to further enhance the results of joint replacement surgeries.",[458],"Knee Osteoarthritis","2024-07-18",{"date":461,"type":32},"2024-07-19",{"date":463,"type":32},"2022-06-03",{"date":465,"type":20},"2024-12-31",{"name":38,"class":39},{"id":468,"slug":469,"hasResults":11,"nctId":470,"briefTitle":471,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":475,"conditions":476,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":130},"100542415","quantitative-analysis-of-eeg-changes-in-response-to-nociception-100542415","NCT06342570","Quantitative Analysis of EEG Changes in Response to Nociception","Inclusion Criteria:\n\n• Patients aged ≥ 19 undergoing laparoscopic surgery\n\nExclusion Criteria:\n\n* Patients with arrhythmia\n* Patients with pacemaker implantation\n* Patients who have received a heart transplant\n* Patients taking medications that may affect ANI (antimuscarinics, alpha-agonist, beta blockers, etc.)\n* Patients with central nervous system disease (dementia, stroke, epilepsy, brain tumor, psychiatric disease, etc.)\n* Patients who cannot understand the consent form",{"count":474,"type":20},109,"This study will quantify the nociception using Analgesia Nociception Index (ANI) during general anesthesia and analyze the differences in EEG depending on the degree of nociception. Additionally, the investigators will quantify the nociception during recovery and analyze the differences in EEG depending on the degree of nociception.",[477],"Patients Undergoing Laparoscopic Surgery","2024-04-28",{"date":480,"type":32},"2024-04-30",{"date":482,"type":32},"2024-04-21",{"date":484,"type":20},"2026-12-30",{"name":38,"class":39},{"id":487,"slug":488,"hasResults":11,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":493,"targetDuration":4,"studyType":21,"phases":495,"briefSummary":496,"conditions":497,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":4},"100515596","phase-3-necessity-of-post-mastectomy-radiotherapy-after-neoadjuvant-chemotherapy-and-mastectomy-100515596","NCT05993559","Necessity of Post-mastectomy Radiotherapy After Neoadjuvant Chemotherapy and Mastectomy","Necessity of Post-mastectomy Radiotherapy in Breast Cancer Patients With an Excellent Response After Neoadjuvant Chemotherapy: A Phase 3, Multicenter, Randomized Controlled Study","Inclusion Criteria:\n\n1. Patients 20 years of age or older with histologically confirmed invasive breast cancer.\n2. Patients with clinical stage IIB-III at the time of diagnosis (including cases of cT1N1 with multiple masses observed during clinical stage IIA). Patients are considered node positive if they have either suspected lymph node metastasis on imaging studies (U\u002FS, breast MRI, PET-CT) or confirmed by pathology.\n3. Patients who have undergone mastectomy after prior neoadjuvant chemotherapy.\n4. Patients with pathologic complete response (pCR) or residual cancer burden (RCB) class 0-I based on postoperative pathology.\n\n   Complete remission is defined as ypT0\u002Fis ypN0. RCB class 0 means complete remission and RCB class 1 is defined as an RCB score ≥0-1.36 as determined by the pathology department at the site.\n5. Patients not previously treated for invasive breast cancer.\n6. Patients with a systemic performance status of 0-2 based on ECOG.\n7. Patients who signed the informed consent prior to study entry.\n\nExclusion Criteria:\n\n1. Patients with a prior history of invasive breast cancer (patients with a prior history of intraepithelial carcinoma of the breast may be enrolled)\n2. Patients with bilateral breast cancer\n3. Patients with a prior diagnosis of cancer other than breast cancer within 5 years (however, adequately treated skin cancer other than melanoma and thyroid cancer are eligible for enrollment.)\n4. Patients with pathologically or imaging confirmed systemic metastases\n5. Patients with a history of prior irradiation or isotope therapy to the rib cage and axillary region contralateral to the breast cancer lesion\n6. Patients with suspected supraclavicular\u002Finfraclavicular lymph node metastases and internal mammary lymph node metastases\n7. Pregnant or lactating patients\n8. Patients who have difficulty understanding the contents of the consent form and completing the survey.",{"count":494,"type":20},1314,[328],"Postoperative radiotherapy is generally recommended for patients with breast cancer who have undergone breast-conserving surgery, regardless of prior chemotherapy. However, the criteria for postoperative radiation therapy (PMRT) in patients with breast cancer who have received upfront chemotherapy and mastectomy remain controversial. PMRT is recommended for patients with suspected axillary lymph node metastases before chemotherapy or residual cancer in the axillary lymph nodes after surgery, but this varies by institution and physician. In particular, breast cancer patients with a very good treatment response (pCR or RCB 0-I after prior chemotherapy) have a very good prognosis, and the question of whether PMRT is necessary for these patients continues to be raised. With the addition of new targeted therapies and immuno-oncology agents to conventional chemotherapy, the number of patients with good response is increasing, but there are no prospective studies to date.\n\nThe studies that have evaluated the need for PMRT in breast cancer patients with a very good treatment response after upfront chemotherapy and mastectomy are all retrospective studies, lacking evidence to apply to standard of care, and have different definitions of a good treatment response group. Therefore, in this study, the investigators aim to reduce unnecessary overtreatment by comparing survival between PMRT and no PMRT in breast cancer patients with a good response to prior chemotherapy and mastectomy, demonstrating non-inferiority of PMRT to no PMRT. By doing so, the investigators hope to reduce patients' side effects and discomfort, improve their satisfaction and quality of life, and contribute to a new standard of care.\n\nThe purpose of this study is to confirm that in patients with breast cancer who have undergone mastectomy after prior neoadjuvant chemotherapy, omitting radiotherapy is non-inferior to post-mastectomy radiotherapy (PMRT) in terms of 5-year disease-free survival (DFS) in patients with pathologic complete remission and a good response to treatment corresponding to RCB class 0-I, compared to patients treated with PMRT.",[90],"2024-01-11",{"date":500,"type":32},"2024-01-12",{"date":502,"type":20},"2024-11-11",{"date":504,"type":20},"2031-07-10",{"name":38,"class":39},{"id":507,"slug":508,"hasResults":11,"nctId":509,"briefTitle":510,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":21,"phases":514,"briefSummary":515,"conditions":516,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":130},"100425254","phase-2-phase-ii-trial-of-anti-her2-treatment-in-her2-enriched-early-breast-cancer-identified-by-pam50-her2e-pam-pamilia-study-100425254","NCT04817540","Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)","Inclusion Criteria:\n\n1. Pathologically and cytologically documented unsectable\u002Fmetastatic breast cancer that :\n\n   A. has confirmed HER2 negative expression regardless hormone receptor status\n   * definition of HER2 negative breast cancer i) HER2 IHC 1+ without ISH or ii) HER2 IHC 2+ and ISH negative (average HER2 gene copy number \\\u003C4 signals\u002Fcell in single probe ISH or HER2\u002FCEP17 ratio \\\u003C2.0 \\& average HER2 gene copy number \\\u003C4 signals cell in dual-probe ISH)\n2. No prior treatment of stage II-III breast cancer\n\n   * HR+ \\& HER2- breast cancer : cT1-4N1-3\n   * HR- \\& HER2- breast cancer : cT1N1-3 or cT2-4N0-3\n3. No systemic metastasis confirmed by pathological or radiological evaluation\n4. Patients over 19 years\n5. Confirmed to HER2-enriched subtype by PAM50 study\n6. Available FFPE 15-20 slides for evaluating PAM50 study\n7. ECOG 0-1\n8. Adequate bone marrow functions i) Hemoglobin≥ 9g\u002FdL ii) ANC ≥1,500\u002Fmm3 iii) Platelet ≥100,000\u002Fmm3\n9. Adequate renal functions i) creatinine : ≤ 1.5 x UNL or ii) creatinine clearance (Ccr) ≥ 50 ml\u002Fmin by Cockroft formula\n10. Adequate liver functions i) Bilirubine : ≤ 1.5 x UNL ii) AST\u002FALT : ≤ 2.5 x UNL\n11. Adequate cardiac functions\n\n    * LVEF ≥50% (with MUGA scan or TTE)\n12. Females of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to first dose of study treatment.\n\nExclusion Criteria:\n\n* 1\\) History of previous treatments of ipsilateral or contralateral invasive breast cancer 2) Confirmation of systemic distant metastasis of breast cancer 3) History of other malignancy within the last 5 years, except curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, less than 2cm of thyroid cancer (papillary, follicular, medullary).\n\n  4\\) inflammatory breast cancer (cT4d) 5) bilateral breast cancer(except, multifocal or multicentric breast cancer) 6) occult breast cancer 7) History of positivity for hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency virus (HIV) 8) Woman of childbearing potential who is not consenting to use highly effective methods of birth control (eg, true abstinence \\[periodic abstinence (eg calendar ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception\\], sterilization, or other non-hormonal forms of contraception) during treatment 9) Uncontrolled infections and other serious diseases or medical conditions 10) Uncontrolled hyeprtension or clinically active cardiovascular disease: for example, cerebrovascular accident or transient isschemic attack, unstable angina, myocaridal infarction within 6 months prior to enrolment. Have symptomatic congestive heart failure (CHF; New York Heart Association II-IV) or symptomatic or poorly controlled cardiac arrhythmia.\n\n  11\\) Have any condition (eg, psychological, geographical, or medical) that does not permit compliance with the study and follow-up procedures or suggest that the patient is, in the investigator's opinion, not an appropriate candidate for the study 12) Patients who are hypesenstivie reaction to experimental drugs (doxorubicin, cyclophosphamide, paclitaxel, docetaxel, herzuma) 13) Peripheral neuropathy CTCAE v4.03 ≥ grade 2",{"count":513,"type":20},59,[161],"In this study, we prospectively analyzed molecular subtyping through the PAM 50 test in HER2-negative (IHC1+ or 2+ (FISH\u002FSISH-)) breast cancer patients. A phase 2 single arm study was designed to determine whether the addition of HER2-targeted treatment with treatment increases the pathologic remission rate.",[517],"HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study","2023-10-09",{"date":520,"type":32},"2023-10-11",{"date":522,"type":32},"2021-09-01",{"date":524,"type":20},"2027-03-30",{"name":38,"class":39},{"id":527,"slug":528,"hasResults":11,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":11,"sex":112,"minAge":17,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":21,"phases":535,"briefSummary":536,"conditions":537,"keywords":538,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":540,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":130},"100419439","repeat-sentinel-lymph-node-biopsy-in-ipsilateral-breast-tumor-recurrence-100419439","NCT04741737","Repeat Sentinel Lymph Node Biopsy in Ipsilateral Breast Tumor Recurrence","Repeat Sentinel Lymph Node Biopsy in Ipsilateral Breast Tumor Recurrence Without Distant Metastasis: A Single-arm, Multicenter, Prospective Study","Inclusion Criteria:\n\n1. Age over 19 years old\n2. Patients who are expected to undergo surgery under the diagnosis of ipsilateral breast tumor recurrence(histologically confirmed in situ disease or invasive disease)\n3. Patients who had partial mastectomy and sentinel lymph node biopsy for prior operation for the initially diagnosed breast cancer\n4. Patients considered to be axillary lymph node negative from clinical findings\n5. Patients who understand and willingly participate in the study\n\nExclusion Criteria:\n\n1. Patients with recurrence in other regions. (e.g. ipsilateral axillary lymph node, supraclavicular lymph node, internal mammary lymph node, etc.)\n2. Patients who are not eligible to perform SLNB\n3. Patients who received mastectomy or axillary lymph node dissection for prior operation\n4. Patients who experienced recurrence within a year from the primary operation\n5. Patientes who are known to have axillary lymph node metastasis before the secondary operation, histologically confirmed from tissue biopsy or cytology\n6. Patients with systemic recurrence\n7. Patients with inflammatory breast cancer\n\n5\\) Pregnant and lactating patients",{"count":534,"type":20},532,[23],"According to the standard treatment guidelines established until recently, in the case of ipsilateral breast tumor recurrence without systemic metastasis, salvage mastectomy or lumpectomy can be performed when either partial or whole breast radiation therapy is possible. On the other hand, there are currently no standard treatment guidelines for axillary treatment, and the evidence for this is limited. Axillary lymph node metastasis was reported to occur in about 26% of breast cancer patients who had negative sentinel lymph nodes from previous surgery for primary breast cancer and only local recurrence occurred. It is still important in the decision of treatment or adjuvant radiation therapy. However, it is known that most of the patients with ipsilateral breast recurrence do not have axillary lymph node metastasis. Therefore, performing axillary axillary surgery in all of these patients does not help the patient's survival in many cases, but rather can lead to complications such as lymphedema and seroma and postoperative wound infection. A question about the implementation of axillary lymph node resection has been raised and for this reason, it is necessary to study whether surveillance lymph node biopsy is still effective in patients with recurrence in the ipsilateral breast.\n\nMost of the studies on ipsilateral breast tumor recurrence without systemic metastasis reported to date are case reports or small retrospective studies. In addition, the combined meta-analysis also has limitations in that the study design is not uniform, and there are many cases in which primary breast cancer surgery performed total mastectomy or axillary lymph node dissection. This study is a multicenter prospective study designed to validate the clinical effectiveness of repeat-SLNB conducted in patients with ipsilateral breast tumor recurrence among patients who previously underwent breast conservation and sentinel lymph node biopsy for unilateral primary breast cancer.",[119],[539],"Breast cancer, Recurrence, Sentinel lymph node biopsy",{"date":520,"type":32},{"date":542,"type":32},"2020-03-01",{"date":544,"type":20},"2029-01-31",{"name":38,"class":39},{"id":547,"slug":548,"hasResults":11,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":552,"eligibilityCriteria":553,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":21,"phases":555,"briefSummary":556,"conditions":557,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":559,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":130},"100415309","primary-surgical-prevention-of-breast-cancer-related-lymphedema-100415309","NCT04687956","Primary Surgical Prevention of Breast Cancer-related Lymphedema","Effect of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) for Primary Surgical Prevention of Breast Cancer-related Lymphedema","LYMPHA","Inclusion Criteria:\n\n1. Age over 19 years old\n2. Patients who are expected to undergo surgery under the diagnosis of breast cancer, and are determined to undergo axillary lymph node dissection before surgery.\n\nExclusion Criteria:\n\n1. Patients with vascular and lymph-related diseases\n2. Patients with a history of surgical treatment or trauma to both arms and axillary\n3. Patients with a history of receiving radiation treatment in both arms, chest, and axilla\n4. Patients with confirmed systemic metastasis with stage 4 breast cancer\n5. Pregnant and lactating patients",{"count":431,"type":20},[23],"Lymphedema refers to edema caused by insufficient drainage of interstitial fluid through the lymphatic circulation system. It occurs mainly in the upper and lower extremities and causes chronic inflammation, and finally fibrous adipose tissue is replaced. In this study, the'LYMPHA' (Lymphatic microsurgical preventing healing approach) procedure, which connects lymphatic vessels drained from the arm to the side branches of the axillary vein, contributes to the prevention of lymphedema in patients undergoing axillary lymph node dissection for breast cancer. Investigator aim to help patients' quality of life by prospectively analyzing the effects and applying them to clinical practice, reducing the incidence of lymphedema.",[558,119,90],"Lymphedema",{"date":520,"type":32},{"date":561,"type":32},"2021-02-01",{"date":563,"type":20},"2027-12-31",{"name":38,"class":39},""]